anti-CD16/anti-CD33/IL-15 trispecific NK-cell engager (GT Biopharma/Altor BioScience)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD16/anti-CD33/IL-15 trispecific NK-cell engager (GT Biopharma/Altor BioScience)
Drug Alias Nameanti-CD16/anti-CD33 antibody (Oxis International/Altor BioScience)anti-CD16/anti-CD33/IL-15 trispecific immune-cell engager (GT Biopharma/Altor BioScience)161533 TriKE with IL-15 superagonist (Oxis/Altor)161533 TriKE with IL-15 superagonist (GT Biopharma/Altor)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsInterleukin-15 receptors agonistsLow affinity immunoglobulin gamma Fc region receptor III agonists
TargetsMyeloid cell surface antigen CD33Interleukin-15 receptorsLow affinity immunoglobulin gamma Fc region receptor III
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGt Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAltor Bioscience CorpGt Biopharma Inc
Active IndicationsN/A
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A